Bavarian Nordic A/S (BVNKF)
Bavarian Nordic A/S operates in the Biotechnology industry of the Healthcare sector, headquartered in Hellerup, CR, DK. The stock last traded at $27.56, down 0.86% on the session, giving a market capitalisation of $2.13B. On trailing twelve-month figures it carries a trailing P/E of 12.38, a net margin of 19.8%. Its beta of 0.94 implies it has historically moved less than the broad market.
Bavarian Nordic A/S engages in the business of developing, manufacturing, and commercializing cancer immunotherapies and vaccines for infectious diseases. The firm is involved in cancer immunotherapy including cancer pipeline, which focuses on therapeutic vaccines for breast, lung, ovarian, and prostate cancer. The company was founded on July 1, 1992 and is headquartered in Hellerup, Denmark.
Bavarian Nordic A/S is most often compared with the following Healthcare names: